Ventura Securities reiterated its Buy rating on Park Medi World and raised its target price to Rs 406 from Rs 284, implying 41.9% upside from Rs 286 over 24 months. The brokerage cited accelerated bed additions, healthy occupancy, improving ARPOB to Rs 30,040, rising super-speciality mix to 61.7%, low capex per bed of Rs 37 lakh, and margin expansion, projecting FY26-FY29E revenue, EBITDA and PAT CAGRs of 26.8%, 28.8% and 33.4% to Rs 3,420 crore, Rs 949 crore and Rs 631 crore respectively.